BRPI0910461B8 - hormônio de estimulação do folículo recombinante, sua composição farmacêutica, seu método de produção e seu uso - Google Patents

hormônio de estimulação do folículo recombinante, sua composição farmacêutica, seu método de produção e seu uso

Info

Publication number
BRPI0910461B8
BRPI0910461B8 BRPI0910461A BRPI0910461A BRPI0910461B8 BR PI0910461 B8 BRPI0910461 B8 BR PI0910461B8 BR PI0910461 A BRPI0910461 A BR PI0910461A BR PI0910461 A BRPI0910461 A BR PI0910461A BR PI0910461 B8 BRPI0910461 B8 BR PI0910461B8
Authority
BR
Brazil
Prior art keywords
production method
stimulating hormone
follicle stimulating
pharmaceutical composition
recombinant follicle
Prior art date
Application number
BRPI0910461A
Other languages
English (en)
Portuguese (pt)
Inventor
Plaksin Daniel
Cottingham Ian
Boyd White Richard
Original Assignee
Ferring Int Center Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0910461(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Int Center Sa filed Critical Ferring Int Center Sa
Publication of BRPI0910461A2 publication Critical patent/BRPI0910461A2/pt
Publication of BRPI0910461A8 publication Critical patent/BRPI0910461A8/pt
Publication of BRPI0910461B1 publication Critical patent/BRPI0910461B1/pt
Publication of BRPI0910461B8 publication Critical patent/BRPI0910461B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006—N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI0910461A 2008-04-16 2009-04-16 hormônio de estimulação do folículo recombinante, sua composição farmacêutica, seu método de produção e seu uso BRPI0910461B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
US61/045,424 2008-04-16
EP08251528.9 2008-04-25
EP08251528 2008-04-25
PCT/GB2009/000978 WO2009127826A1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation

Publications (4)

Publication Number Publication Date
BRPI0910461A2 BRPI0910461A2 (pt) 2018-03-27
BRPI0910461A8 BRPI0910461A8 (pt) 2018-10-16
BRPI0910461B1 BRPI0910461B1 (pt) 2021-02-23
BRPI0910461B8 true BRPI0910461B8 (pt) 2021-05-25

Family

ID=39717519

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910461A BRPI0910461B8 (pt) 2008-04-16 2009-04-16 hormônio de estimulação do folículo recombinante, sua composição farmacêutica, seu método de produção e seu uso

Country Status (29)

Country Link
US (6) US8951967B2 (https=)
EP (7) EP3045471B1 (https=)
JP (7) JP2011519359A (https=)
KR (5) KR20160056960A (https=)
CN (3) CN105906703A (https=)
AR (1) AR071479A1 (https=)
AU (5) AU2009237479B2 (https=)
BR (1) BRPI0910461B8 (https=)
CA (1) CA2725257A1 (https=)
CY (1) CY1115413T1 (https=)
DK (6) DK2808340T3 (https=)
ES (5) ES2468318T3 (https=)
FI (4) FI3098234T3 (https=)
FR (3) FR17C1020I2 (https=)
HR (5) HRP20140535T1 (https=)
HU (9) HUE068565T2 (https=)
IL (2) IL208538A (https=)
LT (8) LT2808340T (https=)
MX (3) MX355457B (https=)
NO (4) NO2017025I1 (https=)
NZ (1) NZ588381A (https=)
PL (6) PL3144318T3 (https=)
PT (6) PT3045471T (https=)
RU (3) RU2682270C2 (https=)
SA (1) SA109300228B1 (https=)
SI (6) SI2268666T1 (https=)
TW (1) TWI488640B (https=)
WO (1) WO2009127826A1 (https=)
ZA (1) ZA201007373B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
PT2621517E (pt) 2010-09-29 2015-10-16 Ferring Bv Composição para uso no tratamento da infertilidade
WO2012050175A1 (ja) 2010-10-15 2012-04-19 日本ケミカルリサーチ株式会社 糖鎖の非還元末端がマンノース残基である糖蛋白質の製造方法
PL2691119T3 (pl) 2011-03-31 2019-01-31 Ferring B.V. Preparat farmaceutyczny
EP2717904A1 (en) 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
WO2013093760A2 (en) * 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
US9657310B2 (en) * 2012-04-27 2017-05-23 Jcr Pharmaceuticals Co., Ltd. Expression vector
EP2824176A1 (en) 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
JP6652334B2 (ja) * 2014-05-31 2020-02-19 Ｊｃｒファーマ株式会社 ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地
WO2016102436A1 (en) * 2014-12-22 2016-06-30 F. Hoffmann-La Roche Ag Cmp-dependent sialidase activity
EP3283097B1 (en) 2015-04-17 2020-02-12 Ferring B.V. Fsh for treatment of infertility
MY179524A (en) 2015-06-26 2020-11-10 Ferring Bv Methods of purification and/or viral inactivation
EP3205719A1 (en) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3382014A1 (en) * 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
MX2020002235A (es) 2017-09-01 2020-07-20 Ferring Bv Composicion para la estimulacion ovarica controlada.
HUE071268T2 (hu) 2018-04-30 2025-08-28 Ferring Bv Készítmény szabályozott petefészek-stimuláláshoz
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
US20220380785A1 (en) * 2019-11-01 2022-12-01 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
KR20240167660A (ko) 2022-04-01 2024-11-27 훼링 비.브이. 불임의 치료를 위한 혼합 프로토콜
AU2023275943A1 (en) 2022-05-26 2024-10-17 Ferring B.V. Compositions and methods for treatment of infertility in males
KR20250033230A (ko) 2022-07-08 2025-03-07 훼링 비.브이. 자궁내 인공수정(iui)을 위한 조성물 및 방법
AR133300A1 (es) 2023-07-20 2025-09-17 Ferring Bv Micropartículas cargadas con fármaco de liberación prolongada

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5541083A (en) 1989-10-24 1996-07-30 The Regents Of The University Of California Method for producing secretable glycosyltransferases and other golgi processing enzymes
IL160406A0 (en) 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
JP3559652B2 (ja) * 1996-06-25 2004-09-02 グローリー工業株式会社 売上精算システムの管理装置
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
JP2001507215A (ja) 1997-01-16 2001-06-05 サイテル コーポレイション 組換え糖タンパク質のインビトロでの実用的なシアリル化
JPH1111665A (ja) 1997-06-28 1999-01-19 Shibuya Kogyo Co Ltd 無菌エア搬送コンベヤ装置
TWI235158B (en) * 1997-09-01 2005-07-01 Kirin Brewery Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same
PT1176976E (pt) 1999-05-07 2006-11-30 Applied Research Systems Utilização de lh administrada na fase folicular média e tardia para o tratamento de mulheres anovulatórias.
JP2002011665A (ja) 2000-06-28 2002-01-15 Sintokogio Ltd ショットブラスト装置モニタシステム
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
MEP38608A (en) * 2001-10-22 2011-02-10 Merck Serono Sa Gonadotrophins for folliculogenesis
ATE542904T1 (de) 2001-10-29 2012-02-15 Crucell Holland Bv Verfahren und mittel zur herstellung von proteinen mit vorbestimmten posttranslationalen modifikationen
PT1465987E (pt) 2001-12-07 2008-04-15 Crucell Holland Bv Produção de vírus, isolados virais e vacinas
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
JP2007515410A (ja) * 2003-12-03 2007-06-14 ネオス テクノロジーズ インコーポレイテッド ＧｌｙｃｏＰＥＧ化卵胞刺激ホルモン
ES2350298T3 (es) 2004-02-04 2011-01-20 Centre National De La Recherche Scientifique Procedimiento para el cribado de anticuerpos específicos de glicoforma.
CN103627670B (zh) * 2004-02-13 2016-12-21 格莱克托普有限公司 高活性糖蛋白加工条件及其有效生产方法
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
US8790322B2 (en) 2010-08-03 2014-07-29 King Saud University Stoma coat
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
PT2621517E (pt) 2010-09-29 2015-10-16 Ferring Bv Composição para uso no tratamento da infertilidade
PL2691119T3 (pl) 2011-03-31 2019-01-31 Ferring B.V. Preparat farmaceutyczny
EP2717904A1 (en) 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
MX2016013449A (es) 2014-04-18 2017-05-04 Glycotope Gmbh Hiperestimulacion ovarica controlada con la hormona estimuladora folicular humana recombinante mejorada.

Also Published As

Publication number Publication date
KR20190092608A (ko) 2019-08-07
EP2268666B1 (en) 2014-03-12
US20240327487A1 (en) 2024-10-03
RU2682270C2 (ru) 2019-03-18
AU2017225020B2 (en) 2019-11-14
HRP20241187T1 (hr) 2024-12-06
AU2014203277C1 (en) 2017-07-27
HUS1700025I1 (hu) 2017-06-28
RU2014141994A3 (https=) 2018-05-28
US11952407B2 (en) 2024-04-09
JP2018021037A (ja) 2018-02-08
DK4015527T3 (da) 2025-04-14
CN105906703A (zh) 2016-08-31
ES2989729T3 (es) 2024-11-27
IL230571A (en) 2015-11-30
US9546204B2 (en) 2017-01-17
JP2020040956A (ja) 2020-03-19
AU2009237479A1 (en) 2009-10-22
HUS1700036I1 (hu) 2017-10-30
RU2014141994A (ru) 2016-05-10
PT3098234T (pt) 2024-10-21
ES2629392T3 (es) 2017-08-09
ES3023526T3 (en) 2025-06-02
RU2537268C2 (ru) 2014-12-27
SI3045471T1 (sl) 2017-07-31
BRPI0910461A2 (pt) 2018-03-27
AU2017225020A1 (en) 2017-09-28
PT2268666E (pt) 2014-06-25
US20150065695A1 (en) 2015-03-05
LT2808340T (lt) 2016-11-10
CY1115413T1 (el) 2017-01-04
IL208538A (en) 2014-03-31
US20110105398A1 (en) 2011-05-05
SI3144318T1 (sl) 2020-12-31
PT2808340T (pt) 2016-11-21
AU2009237479B2 (en) 2014-05-15
CN102066414A (zh) 2011-05-18
DK3045471T3 (en) 2017-06-26
US20180079794A1 (en) 2018-03-22
FR17C1020I2 (fr) 2020-04-10
HRP20250313T1 (hr) 2025-05-09
CA2725257A1 (en) 2009-10-22
US9771407B2 (en) 2017-09-26
EP3144318A1 (en) 2017-03-22
MX2010011343A (es) 2011-01-20
PL4015527T3 (pl) 2025-05-26
MX348622B (es) 2017-06-22
US20160347811A1 (en) 2016-12-01
US8951967B2 (en) 2015-02-10
EP2268666A1 (en) 2011-01-05
RU2745557C1 (ru) 2021-03-29
LT3045471T (lt) 2017-07-10
HUE068565T2 (hu) 2025-01-28
PT4015527T (pt) 2025-04-10
RU2745557C3 (ru) 2021-12-10
JP2017060476A (ja) 2017-03-30
AU2014203277A1 (en) 2014-07-24
SI4015527T1 (sl) 2025-05-30
FIC20250025I1 (fi) 2025-07-11
EP3045471B1 (en) 2017-03-29
DK2808340T3 (en) 2016-12-05
LT4015527T (lt) 2025-04-10
SI2808340T1 (sl) 2016-12-30
KR20170110741A (ko) 2017-10-11
KR102108377B1 (ko) 2020-05-08
HRP20161520T1 (hr) 2016-12-30
AU2017204258A1 (en) 2017-07-20
EP3045471A1 (en) 2016-07-20
EP3098234B1 (en) 2024-07-31
DK2268666T3 (da) 2014-05-12
NO2017050I1 (no) 2017-09-28
LTPA2025525I1 (https=) 2025-07-25
PL3098234T3 (pl) 2025-01-07
PT3045471T (pt) 2017-06-14
KR101622944B1 (ko) 2016-05-23
LTPA2017018I1 (lt) 2017-06-26
KR20180095140A (ko) 2018-08-24
FR25C1003I1 (fr) 2025-02-28
AU2017204259A1 (en) 2017-07-20
AU2014203277B2 (en) 2017-04-06
EP2808340B1 (en) 2016-08-17
CN105906702A (zh) 2016-08-31
JP2015120696A (ja) 2015-07-02
ZA201007373B (en) 2011-06-29
HK1199039A1 (en) 2015-06-19
JP6762916B2 (ja) 2020-09-30
NO2025032I1 (no) 2025-07-14
DK3098234T3 (da) 2024-10-21
PL2268666T3 (pl) 2014-08-29
JP2022031652A (ja) 2022-02-22
HUE030652T4 (en) 2017-09-28
EP3098234A1 (en) 2016-11-30
HUE030652T2 (en) 2017-05-29
US12516094B2 (en) 2026-01-06
SI3098234T1 (sl) 2024-10-30
EP2808340A1 (en) 2014-12-03
TWI488640B (zh) 2015-06-21
RU2010141908A (ru) 2012-05-27
PL2808340T3 (pl) 2017-02-28
NZ588381A (en) 2012-05-25
DK3144318T3 (da) 2020-12-07
EP2722339A1 (en) 2014-04-23
FI3098234T3 (fi) 2024-10-31
JP7316905B2 (ja) 2023-07-28
ES2610277T3 (es) 2017-04-26
HK1146284A1 (en) 2011-05-20
AU2017204258B2 (en) 2017-08-17
EP4015527A1 (en) 2022-06-22
PL3045471T3 (pl) 2017-10-31
PL3144318T3 (pl) 2021-02-08
JP2024038000A (ja) 2024-03-19
FR17C1020I1 (https=) 2020-04-10
HUE033830T2 (en) 2018-01-29
EP3144318B1 (en) 2020-09-23
LTPA2025505I1 (https=) 2025-02-10
JP2011519359A (ja) 2011-07-07
TW200948378A (en) 2009-12-01
KR20160056960A (ko) 2016-05-20
US10995128B2 (en) 2021-05-04
WO2009127826A1 (en) 2009-10-22
AR071479A1 (es) 2010-06-23
HRP20170958T1 (hr) 2017-09-22
HRP20140535T1 (hr) 2014-07-18
JP6486310B2 (ja) 2019-03-20
KR20110005863A (ko) 2011-01-19
NO2017025I1 (no) 2017-06-06
HUS2500029I1 (hu) 2025-07-28
BRPI0910461A8 (pt) 2018-10-16
FIC20250003I1 (fi) 2025-01-15
FI4015527T3 (fi) 2025-04-29
HUS2500008I1 (hu) 2025-02-28
EP4015527B1 (en) 2025-01-22
MX355457B (es) 2018-04-19
SA109300228B1 (ar) 2014-04-08
NO2025006I1 (no) 2025-01-16
PT3144318T (pt) 2020-11-04
ES2468318T3 (es) 2014-06-16
BRPI0910461B1 (pt) 2021-02-23
FR25C1025I1 (fr) 2025-09-19
HUE071059T2 (hu) 2025-07-28
SI2268666T1 (sl) 2014-07-31
AU2017204259B2 (en) 2017-08-17
IL208538A0 (en) 2010-12-30
HUS1700024I1 (hu) 2017-06-28
LT3098234T (lt) 2024-09-10
US20210332099A1 (en) 2021-10-28
LTPA2017029I1 (lt) 2017-10-10

Similar Documents

Publication Publication Date Title
BRPI0910461B8 (pt) hormônio de estimulação do folículo recombinante, sua composição farmacêutica, seu método de produção e seu uso
BRPI0805826B8 (pt) compostos espiro-substituídos, composição farmacêutica e uso
CL2007003635A1 (es) Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer.
MX2019012081A (es) Proteina de fusion del factor de crecimiento 21 de fibroblastos humanos (hfgf21), metodo de preparacion de la misma y su uso.
EP2390265A3 (en) Insulinotropic peptide derivative wherein its N-terminal amino acid is modified
BRPI0816784A8 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
BR0308429A (pt) Aroilpiridinonas monocìclicas como agentes antiinflamatórios
BR112012013164A2 (pt) composições farmacêuticas para o estímulo de células-tronco
WO2011144673A3 (en) Long - acting formulations of insulins
CL2007002610A1 (es) Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras.
CL2009002206A1 (es) Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
UY29410A1 (es) Composiciones farmacéuticas en base a metilamidas del ácido 4-(4-/-3(-4-cloro-3-trifluorometifenil)ureido)fenoxi)piridin-2-carboxílico, procedimiento de preparación y aplicaciones.
BR112015032559A8 (pt) cerâmica odontológica de zircônia, artigo odontológico, e seu método de fabricação
SG158870A1 (en) Bendamustine pharmaceutical compositions for lyophilisation
BR112012027759A2 (pt) Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso
CL2008003537A1 (es) Compuestos derivados de 2-amino-pirimidina, antagonistas de receptores h4; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad alergica, inmunologica o inflamatoria o dolor.
EP3501546A3 (de) Cystein-wirkstoff konjugate und ihre verwendung
NZ702801A (en) Treatment of sanfilippo syndrome type b
BRPI0618488A2 (pt) proteìnas de fusão de ìntron de fator de crescimento de hepatócito
CO5640037A2 (es) Derivados de la quinazolina para el tratamiento del cancer
CR10092A (es) Nuevos derivados de furopirimidina aciclicos sustituidos y su uso
PH12015502755A1 (en) Insulin glargine / lixisenatide fixed ratio formulation
BRPI1012666B8 (pt) cocristal de etravirina e nicotinamida, composição farmacêutica, combinação compreendendo o mesmo, seu processo para a preparação e uso
MX2021011596A (es) Compuestos y composiciones como moduladores de se?alizacion tlr.
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/04/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF